-
Mashup Score: 48
Advances in systemic therapy for NSCLC may change the paradigm of eligibility for surgery. This study demonstrates that surgical resection of the primary tumor is associated with improved overall survival in selected patients with single-site oligometastatic disease.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20American Association for Thoracic Surgery (AATS) on LinkedIn: Next up on our Best of AATS 2024 webinar series: Thoracic content. See… - 2 day(s) ago
Next up on our Best of AATS 2024 webinar series: Thoracic content. See highlights from various tracks such as esophageal, lung transplant, and thoracic…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16
A video from Brendon Stiles, posted on Apr 29, 2024.
Source: www.vumedi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer - PubMed - 17 day(s) ago
Purpose In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after th …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@DrewMoghanaki @huroqu90 @MKamelHusseinMD @nchudgar @EinsteinMed @AATSHQ @AATSJournals But we modeled it on a previous paper from @JCO_ASCO using the same NCDB. This one agreed w/ your preconceived notions. I don’t remember you attacking the methodology on that one. You may have even promoted it. Please remind me… 🙏 https://t.co/qsI0tsdt5l
-
-
Mashup Score: 6Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer - 18 day(s) ago
Purpose In early-stage non–small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after these interventions using the National Cancer Database. Patients and Methods We abstracted patients with cT1-T2a, N0, M0 NSCLC diagnosed between 2004 and 2013 undergoing either surgery or SBRT. Thirty-day and 90-day post-treatment mortality rates were calculated and compared using Cox regression and propensity score–matched analyses. Results We identified 76,623 patients who underwent surgery (78% lobectomy, 20% sublobar resection, 2% pneumonectomy) and 8,216 patients who received SBRT. In the unmatched cohort, mortality rates were moderately increased with surgery versus SBRT (30 days, 2.07% v 0.73% [absolute difference (Δ), 1.34%]; P < .001; 90 days, 3.59% v 2.93% [Δ, 0.66%]; P < .001). Amon
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer - 1 month(s) ago
The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small cell lung cancer (SCLC). This study evaluated prognostic factors affecting the risk of thoracic progression in ES-SCLC patients likely to undergo thoracic …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Abstract. Radiotherapy may induce off-target antitumor “abscopal” immunostimulatory but also immunosuppressive effects. Several preclinical and early clini
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Treatment Decision Drivers in Stage III Non–Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States - 2 month(s) ago
PURPOSE: We conducted a cross-sectional survey of practicing medical oncologists in the United States to obtain insight into physician and patient treatment decision making in stage III non–small-cell lung cancer (NSCLC). METHODS: A convenience sample of 150 oncologists completed a 38-question Web-based survey in January 2019. RESULTS: Surveyed oncologists (82% community based) had an average of 15 years of clinical experience and had treated an average of 20 patients newly diagnosed with stage III NSCLC in the previous 6 months. Oncologists reported presenting 55% of their patients with stage III NSCLC to tumor boards. For patients with new unresectable stage III NSCLC seen in the previous 6 months, concurrent chemoradiation therapy (cCRT) was reported as the initial treatment in an average of 48% of patients. The most frequent reason for delays in starting the initial chosen treatment was insurance preauthorization processes (reported by 65% of oncologists). A total of 55% of all pat
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43
At the Forefront of Cardiothoracic Surgery, AATS members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease.
Source: www.aats.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38th Zurich Immuno-Oncology Symposium - 2 month(s) ago
The 8th Zurich Immuno-Oncology Symposium will bring together clinicians and scientists from across the field of cancer immunotherapy to deepen the understanding of cancer, the immune system and immunotherapy.
Source: www.usz.chCategories: General Medicine News, Hem/OncsTweet
Congratulations @huroqu90 on this publication in @acsJACS! Nice association of surgery for the primary tumor with improved survival for carefully selected patients with single site oligometastatic NSCLC. We are interested in exploring this prospectively! https://t.co/cgUCWQuHNl https://t.co/GczdWnxaFb